Related Experiment Videos
Prostacyclin enhances embryo hatching but not sperm motility
J-C Huang1, W-S A Wun, J S Goldsby
1Obstetrics and Gynecology-Division of Reproductive Endocrinology and Vascular Biology Research Center, University of Texas-Houston Health Science Center, Houston, TX 77030, USA. jaou-chen@uth.tmc.edu
Human Reproduction (Oxford, England)
|December 3, 2003
Summary
Prostacyclin (PGI(2)) enhances mouse embryo hatching but does not impact human sperm motility, offering new insights into reproductive biology and potential therapeutic targets.
Area of Science:
- Reproductive Biology
- Molecular Endocrinology
- Embryology
Background:
- Human oviducts synthesize abundant prostacyclin (PGI(2)).
- PGI(2) is crucial for endometrial decidualization.
- The impact of PGI(2) on sperm and embryos remained largely unexplored.
Purpose of the Study:
- To investigate the effects of PGI(2) on human sperm function.
- To determine the influence of PGI(2) on early embryo development, specifically mouse embryo hatching.
- To examine the expression and binding of the PGI(2) receptor (IP) in embryos.
Main Methods:
- Computer-assisted semen analysis assessed human sperm motility.
- Mouse embryo hatching rates were evaluated after iloprost exposure.
- Western blot, immunohistochemistry, and radioligand binding assays analyzed IP expression and PGI(2) binding.
- cAMP levels in embryos were measured.
Main Results:
- Iloprost did not affect human sperm motility or survival.
- Iloprost significantly enhanced mouse embryo hatching, with critical effects during specific developmental stages.
- The PGI(2) receptor (IP) was expressed in a developmental stage-specific manner in embryos.
- Iloprost bound to blastocysts, but did not significantly increase intracellular cAMP levels.
Conclusions:
- Prostacyclin (PGI(2)) promotes mouse embryo hatching.
- PGI(2) does not influence human sperm motility.
- The findings suggest a specific role for PGI(2) in early embryonic development, independent of sperm function.